Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Radiation Therapy in Locally Advanced NSCLC
NCT02492867Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jan 2016
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Open-label trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Number of Patients for Whom Treatment is Feasible at 6 weeks and Number of Patients That Experience Grade 2 or Greater Lung Toxicity at 24 months. Started Jan 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02492867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492867.